Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Petach Tikva, Israel Clinical Trials

A listing of Petach Tikva, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (658) clinical trials

Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

This is a multi-center prospective cohort study in which the investigators are aim to enroll 120 children under the age of 18 years, diagnosed with CD, inflammatory bowel disease unclassified (IBDU) or UC (approximately 60 in UC/IBDU and 60 in the CD group) who commenced on Vedolizumab for any reason …

Phase N/A

0.0 miles

Learn More »

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Bloodstream infections are a common and serious problem, affecting 15% of critically ill patients, increasing length of hospital stay by 2-3 weeks, adding $25,000-40,000 in excess hospital costs, and tripling the risk of death. At the same time, antibiotic overuse is also a common and serious problem, in that 30-50% …

Phase N/A

0.0 miles

Learn More »

Prostate Cancer Screening Among Men With High Risk Genetic Predisposition

This will be a prospective diagnostic trial of screening for prostate cancer among men with genetic predisposition. The target population is males (40-70 year old) carrying a BRCA1 and/or BRCA2 germ line mutation. They will be identified via our Genetic counseling unit. All men after signing an informed consent will …

Phase N/A

0.0 miles

Learn More »

Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage

Brief Summary: Screening programs for high-grade ovarian carcinoma failed to reduce disease-specific mortality, since they do not offer early enough detection of the disease. Most cases of high grade ovarian cancer develop in the fallopian tubes, hence the universal recommendation for high-risk populations (e.g., BRCA1/2 mutation carriers) is to undergo …

Phase N/A

0.0 miles

Learn More »

Optimal Antibiotic Treatment of Moderate to Severe Bacterial Infections

Severe bacterial infections are associated with mortality of about 30%. Patients with moderate to severe bacterial infections given early and appropriate empirical antibiotic treatment are at a lesser risk for a fatal outcome, with odds ratios ranging from 1.6 to 6.9. However only about 2/3 of patients worldwide are given …

Phase

0.0 miles

Learn More »

Gut Microbiome and Gestational Diabetes Mellitus

The gut microbiome: The human body is colonized by a multitude of microorganisms whose collective genome, the microbiome, complements and enhances our own genome. From this perspective, humans are "supra-organisms" colonized by a number of microbial cells that is 10 times greater than the sum of all our human somatic …

Phase N/A

0.0 miles

Learn More »

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastasessor

Patients will receive AZD9291 at a dose of 80 mg once daily. Intracranial response will be assessed with brain MRI scan, systemic evaluation will be done by PET-CT scan. In case of isolated CNS progression which may or may not be accompanied by asymptomatic systemic progression, and having in mind …

Phase

0.0 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

This study is designed to evaluate how the body processes and removes mirikizumab. The study will also evaluate safety and disease response in pediatric participants with UC taking mirikizumab. The study will last about 52 weeks and may include up to 17 visits.

Phase

0.0 miles

Learn More »

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in reducing the frequency of cough-induced SUI …

Phase

0.0 miles

Learn More »

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior …

Phase

0.0 miles

Learn More »